Medulloblastoma in childhood: new biological advances

@article{Crawford2007MedulloblastomaIC,
  title={Medulloblastoma in childhood: new biological advances},
  author={John R Crawford and Tobey J. MacDonald and Roger J. Packer},
  journal={The Lancet Neurology},
  year={2007},
  volume={6},
  pages={1073-1085}
}
Medulloblastoma is the most common embryonal tumour in children. Patients with medulloblastoma are currently staged as average-risk or poor-risk on the basis of clinical findings. With current multimodality therapy, nearly 90% of children with average-risk, non-disseminated medulloblastoma have 5-year event-free survival, and those with high-risk disease have a 60-65% survival rate; however, the outcome for younger children, particularly infants, is worse. Children who survive medulloblastoma… Expand
Genetics of medulloblastoma: clues for novel therapies
TLDR
The signaling pathway alterations implicated in medulloblastoma pathogenesis, the techniques used in molecular profiling of these tumors and recent molecular subclassification schemes are discussed, with particular emphasis given to the identification of novel molecular targets for less toxic, patient-tailored therapeutic approaches. Expand
The molecular genetics of medulloblastoma: an assessment of new therapeutic targets
TLDR
Research is required to increase the understanding of the basic biology of medulloblastoma, helping to refine patient stratification, decrease side effects of treatments, identify novel prognostic markers, and discover new less toxic therapies. Expand
Molecular Classification of Medulloblastoma
TLDR
It is suggested that MB is a heterogeneous disease, and that MB subgroups have distinct molecular, demographic, and clinical characteristics, and the molecular classification of MBs is redefining the risk stratification of patients with MB, and has the potential to identify new therapeutic strategies for the treatment of MB. Expand
Pathological and molecular heterogeneity of medulloblastoma
TLDR
Better understanding of the growth control mechanisms involved in the development and progression of medulloblastoma will allow improved therapeutic stratification of patients using existing adjuvant therapy as well as the development of new therapeutic approaches. Expand
Medulloblastoma—Biology and Microenvironment: A Review
TLDR
This review seeks to highlight several key processes observed in cancer biology, particularly the involvement of the tumor microenvironment, with relevant examples from Medulloblastoma. Expand
Genomic Characterization of Medulloblastoma
TLDR
The extent of heterogeneity that exists in the medulloblastoma genome is demonstrated, showing that relatively few genomic aberrations are common when studying medullOBlastoma as a single disease. Expand
Epigenetic-Based Therapy—A Prospective Chance for Medulloblastoma Patients’ Recovery
TLDR
This review presents the currently known epigenetic mechanisms that are involved in medulloblastoma pathogenesis and the potential therapies that use epigenetic traits to cure medullOBlastoma while maintaining a good quality of life and ensuring a higher median overall survival rate. Expand
Medulloblastoma – Molecular Genetics
TLDR
Medulloblastoma is an embryonal brain tumor of the cerebellum that is the most common malignant brain tumor in children representing 15–30% of all pediatric brain tumors, with 85% of MB being diagnosed in patients younger than 18 years of age. Expand
Risk-adapted chemotherapy in childhood medulloblastoma
  • A. Varan
  • Medicine
  • Expert review of anticancer therapy
  • 2011
TLDR
Examination of the use of chemotherapy in childhood medulloblastoma according to risk group found the amount and the extent of metastases, surgery and age were the most important prognostic factors. Expand
Medulloblastoma : cell of origin & hereditary cancer syndromes
www.expert-reviews.com ISSN 1473-7175 © 2010 Expert Reviews Ltd 10.1586/ERN.10.31 Medulloblastoma is a primitive neuroectodermal tumor of the cerebellum. Within the pediatric population,Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 108 REFERENCES
Current treatment of medulloblastoma: recent advances and future challenges.
TLDR
Treatment for average-risk Medulloblastoma has achieved a level of success that allows efforts to be focused on the limitation of adverse treatment effects, and therapy for high-risk and relapsed MB has been positively affected by the advent of high-dose chemotherapy with stem cell rescue. Expand
Current therapy for medulloblastoma
TLDR
It is envisaged that in the near future children diagnosed with medulloblastoma will be more accurately stratified based on a combination of clinical variables and molecular profiles, which will permit delivery of individualized therapy using conventional treatment modalities in conjunction with novel targeted therapeutic approaches. Expand
Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.
TLDR
Conventional chemotherapy alone can be used to cure children with non-metastatic medulloblastoma who have gross total resection confirmed by early radiological assessment, but is not sufficient for treatment of those with metastatic or incompletely resected medullOBlastoma. Expand
Medulloblastoma: Therapy and biologic considerations
TLDR
Mouse medulloblastoma models may provide an important bridge between biologic investigation and the development of new therapeutic approaches, and current standard and investigational treatments do not yet make use of biologic markers that predict risk of recurrence. Expand
Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.
TLDR
Postoperative chemotherapy alone is a promising treatment for medulloblastoma in young children without metastases in children who have complete resection, residual tumor, and macroscopic metastases. Expand
Pathogenesis of medulloblastoma and current treatment outlook
TLDR
The current review presents recent developments in medulloblastoma pathophysiology research and proposed inhibitors that could constitute good candidates for further pharmacological research. Expand
Adult Medulloblastoma: Prognostic Factors and Patterns of Relapse
TLDR
Late relapse is common among adult patients with medulloblastomas, and long-term follow-up monitoring is important, and the role of chemotherapy for this group of patients needs to be further investigated. Expand
What's new in neuro-oncology? Recent advances in medulloblastoma.
TLDR
The current histopathological classification system for medulloblastoma is reviewed and a review of how future efforts in this disease will seek to translate knowledge of disease biology into clinical practice is concluded. Expand
Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study.
  • R. Packer, J. Goldwein, +8 authors J. Boyett
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
The results suggest that reduced-dose craniospinal radiation therapy and adjuvant chemotherapy during and after radiation is a feasible approach for children with nondisseminated medulloblastoma. Expand
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
TLDR
Investigating the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma found it can be used to improve the outcome of patients with high-risk medullOBlastoma. Expand
...
1
2
3
4
5
...